삼성바이오는 지난해 11월까지만 해도 시총 순위가 12∼14위를 오갔으나 실적 개선을 바탕으로 빠르게 순위를 끌어올리며 3위까지 치고 올라왔다.
As recently as November last year, Samsung Bio's market capitalization ranking was between 12th and 14th, but it quickly climbed to third place based on improved performance.